+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of rat anti-mouse interleukin 3 monoclonal antibodies which neutralize bioactivity in vitro



Development of rat anti-mouse interleukin 3 monoclonal antibodies which neutralize bioactivity in vitro



Journal of Immunology 140(1): 131-137



Several rat anti-mouse interleukin 3 (IL-3) monoclonal antibodies have been developed which inhibit the biologic activity of mouse IL-3. These antibodies were produced in rats immunized with preparations of purified, recombinant mouse IL-3, obtained from transiently transfected COS7 cell supernatant. Hybridomas secreting anti-IL-3 were selected initially either on the basis of their giving a positive signal in an indirect enzyme-linked immunosorbent assay, or for their ability to inhibit the proliferation of the IL-3-dependent mouse mast cell line, MC/9. Neutralizing rat monoclonal IgG1, IgG2a, and IgG2b antibodies have been identified; these also block IL-3-induced proliferation of the NFS-60 and IC2 cell lines. These antibodies also blocked the IL-3-induced proliferation of mouse bone marrow-derived colony-forming units-culture suggesting that the same epitopes on IL-3 influence receptor recognition for both the proliferation of factor-dependent cell lines as well as normal bone marrow cells. Fab fragments produced from certain of the IgG2a-neutralizing antibodies blocked as well as the parent IgG. Antibody cross-blocking studies identified one neutralizing antibody apparently recognizing an epitope that was spatially distinct from those recognized by the other blocking antibodies tested. The development of these neutralizing rat monoclonal antibodies to mouse IL-3 should facilitate further investigation on the role of this factor in hemopoietic regulation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039795012

Download citation: RISBibTeXText

PMID: 2447167


Related references

Maternally derived recombinant human anti-hantavirus monoclonal antibodies are transferred to mouse offspring during lactation and neutralize virus in vitro. Journal of Virology 80(8): 4183-4186, 2006

Monoclonal antibodies that recognize human granulocyte-macrophage colony-stimulating factor and neutralize its bioactivity in vitro. Hybridoma 9(6): 545-558, 1990

Anti-erythropoietin receptor (EPO-R) monoclonal antibodies inhibit erythropoietin binding and neutralize bioactivity. Blood 82(1): 46-52, 1993

The development of mouse monoclonal antibodies that bind and neutralize paraquat. Developments in Biological Standardization 66: 495-501, 1987

Monoclonal antibodies specific for rat relaxin. I. Production and characterization of monoclonal antibodies that neutralize rat relaxin's bioactivity in vivo. Endocrinology 123(5): 2472-2478, 1988

Monoclonal antipeptide antibodies recognize IL-3 and neutralize its bioactivity in vivo. Journal of Immunology 140(4): 1182-1187, 1988

Antipeptide antibodies of predetermined specificity recognize and neutralize the bioactivity of the pan-specific hemopoietin interleukin 3. Journal of Immunology 138(4): 1099-1104, 1987

Development of a murine ige immunoassay and an in vitro ige antibody system with monoclonal rat anti mouse ige antibodies. FASEB Journal 3(4): A1117, 1989

Two monoclonal antibodies that neutralize human interleukin 1 alpha. Federation Proceedings 46(3): 782, 1987

Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies. Journal of Interferon Research 14(5): 301-302, 1994

Failure to detect interleukin (IL)-3 mRNA or protein in human keratinocytes: antibodies to granulocyte macrophage-colony-stimulating factor or IL-6 (but not IL-3) neutralize "IL-3" bioactivity. Journal of Investigative Dermatology 104(3): 335-339, 1995

Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-alphaGal antibodies. Transplantation 62(6): 837-843, 1996

Anti-idiotypic antibodies to monoclonal antibodies that neutralize coxsackievirus B4 do not recognize viral receptors. Virology 150(2): 352-360, 1986

Development of syngeneic monoclonal anti-idiotype antibodies to mouse monoclonal anti-asialoglycoprotein receptor antibody. Acta Medica Okayama 56(3): 135-139, 2002

Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Research 49(14): 3783-3788, 1989